Nuvation Bio prices $200M convertible notes offering due 2032 to repay debt and fund operations

Filed June 25, 2026 · ~1 min read

Key Changes

• high

  Nuvation Bio is offering $200 million principal amount of convertible senior notes due July 1, 2032 (plus up to $30 million over-allotment option). Interest rate and conversion price are not yet disclosed in this preliminary prospectus.

  The Offering verify on EDGAR →
• high

  Proceeds will fund capped call transactions to hedge dilution, fully repay the $50 million Loan Agreement, and support general corporate purposes including working capital and operating expenses.

  Use of Proceeds verify on EDGAR →
• high

  After the offering and debt repayment, total consolidated indebtedness for borrowed money will increase from $55.8 million to $205.8 million (assuming no over-allotment exercise).

  The Offering verify on EDGAR →